DK200101219A - Fremgangsmåde til fremstilling af citalopram - Google Patents
Fremgangsmåde til fremstilling af citalopram Download PDFInfo
- Publication number
- DK200101219A DK200101219A DK200101219A DKPA200101219A DK200101219A DK 200101219 A DK200101219 A DK 200101219A DK 200101219 A DK200101219 A DK 200101219A DK PA200101219 A DKPA200101219 A DK PA200101219A DK 200101219 A DK200101219 A DK 200101219A
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- formula
- compound
- aryl
- alkylamino
- Prior art date
Links
- 0 CN(C)CCCC1(c(cc2)ccc2[Fl])OCc2cc(C(O)=O)ccc12 Chemical compound CN(C)CCCC1(c(cc2)ccc2[Fl])OCc2cc(C(O)=O)ccc12 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Steroid Compounds (AREA)
Description
Krav 1. En fremgangsmåde til fremstilling af citalopram omfattende
omdannelse af en forbindelse med formlen VIII hvori Z er halogen,
til en forbindelse med formlen IV
efterfulgt af omdannelse af forbindelsen med formlen IV til citalopram. 2. En fremgangsmåde i føgle krav 1, kendetegnet ved at: i) Forbindelsen med formlen IV reageres med et dehydratiseringsmiddel og et sulfonamid med formlen H2N-S02-R, hvori R er: a) en eventuelt substitueret NH2 eller alkyloxy, b) aryloxy eller heteroaryloxy eventuelt substitueret med halogen, Ci-4-alkyl, cyano, hydroxy, Ci-4-alkoxy, trifluoromethyl, nitro, amino, Ci-4-alkylamino eller di-Ci.4-alkylamino, eller c) aryl eller heteroaryl eventuelt substitueret med halogen, Ci^-alkyl, cyano, hydroxy, Ci-4-alkoxy, trifluormethyl, nitro, amino, C|.4-alkylamino eller di-Cu-alkylamino; eller
ii) forbindelsen med formlen IV omdannes til det tilsvarende amid med formlen V
hvori R1 og R2 uafhængigt er hydrogen, Ci-6 alkyl, Q-e alkyl substitueret med én eller flere substituenter valgt blandt gruppen bestående af aryl og heteroaryl, hydroxy, Ci-e-alkoxy, aryloxy, aryl-Ci.^-alkoxy eller trisubstitueret silyl, hvori substituenteme uafhængigt er Ci-6 alkyl, aryl, heteroaryl eller aryl-C|.6-alkyl, og derefter reagere amidet med formlen V med et dehydratiseringmiddel hvorved der opnås citalopram som den fri base eller et farmaceutisk acceptabelt salt deraf. 3. Fremgangsmåde ifølge krav 2, hvori forbindelsen med formlen IV reageres med SOCI2 og sulfamid. 4. Fremgangsmåden ifølge krav 3, kendetegnet ved, at reaktionen udføres i sulfolan. 5. Fremgangsmåden ifølge krav 2, hvori forbindelsen med formlen IV reageres med POCI3 og /er/-butylamin. 6. Fremgangsmåden ifølge krav 1, kendetegnet ved, at forbindelsen med formlen IV opnås ved:
i) at reagere forbindelsen med formlen VIII hvori Z er halogen,
med Mg eller en organolithium-forbindelse, f.eks. n-BuLi, eller med et organometallisk kompleks bestående af Mg og/eller Mn og/eller Li og alkyl- eller arygrupper for at opnå et første mellemprodukt;
ii) efterfølgende reagere nævnte første mellemprodukt med CO2, CS2 eller en forbindelse med formlen IX
hvori A og X er uafhængigt valgt blandt halid, CN, OR5 eller SR6, hvori R5 og R6 er uafhængigt valgt blandt Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino, NR7R8, hvor R7 og R8 er uafhængigt vlagt blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino; Y er O, S eller NR9, hvor R9 er valgt blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, C]-4 alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino; for at opnå et andet mellemprodukt; iii) og efterfølgende reagere nævnte andet mellemprodukt med vand, en hydroxid såsom NaOH eller en vandig opløsning af en syre.
7. Fremgangsmåden ifølge krav 1, kendetegnet ved at forbindelsen med formlen IV opnås ved at koble en forbindelse med formlen VIII
hvori Z er Br eller 1 med en eventuelt substitueret vinyl- eller acetylengruppe ved tilstedeværelse af en metalkatalysator, såsom en nikkel eller palladiumbaseret katalysator, efterfulgt af oxidation af vinyl- eller acetylengruppen til carboxy, hvorved der opnås forbindelsen med formlen IV. 8. En fremgangsmåde til fremstilling af en forbindelse med formlen IV omfattende
omdannelse af en forbindelse med formlen VIII
hvor Z er halogen, til en forbindelse med formlen IV. 9. Fremgangsmåden ifølge krav 8, kendetegnet ved, at forbindelsen med formlen IV opnås ved:
i) at reagere forbindelsen med formlen VIII
hvori Z er halogen, med Mg eller en organolithium-forbindelse, f.eks. n-BuLi, eller med et organometallisk kompleks bestående af Mg og/eller Mn og/eller Li og alkyl- eller arylgrupper for at opnå et første mellemprodukt;
ii) efterfølgende at reagere nævnte første mellemprodukt med CO2, CS2 eller en forbindelse med formlen IX
hvori A og X vælges uafhængigt blandt halid, CN, OR5 eller SR6, hvor R5 og R6 vælges uafhængigt blandt C 1.6 alkyl, aryl, heteroaryl eller benzyl og hver af disse C ι-e alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substituret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino, NR7R8, hvor R7 og R8 vælges uafhængigt blandt hydrogen, C 1.6 alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzyl-grupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino; Y er O, S eller NR9, hvor R9 vælges blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino; for at opnå et andet mellemprodukt; iii) og efterfølgende at reagere nævnte andet mellemprodukt med vand, et hydroxid såsom NaOH eller en vandig opløsning af en syre.
10. Fremgangsmåden ifølge krav 8, kendetegnet ved at forbindelsen med formlen IV opnås ved at koble en forbindelse med formlen VIII
hvori Z er Br eller I, med en eventuelt substitueret vinyl- eller acetylengruppe ved tilstedeværelse af en metalkatalysator, såsom en nikkel- eller palladiumbaseret katalysator, efterfulgt af oxidation af vinyl- eller acetylengruppen til carboxy, hvorved der opnås en forbindelse med formlen IV.
11. En fremgangsmåde til fremstilling af en forbindelse med formlen VII
hvori X vælges blandt halid, CJN, OK' eller SK', hvor K' og K' vælges ualhængigt blandt Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino, NR7R8, hvor R7 og R8 uafhængigt vælges blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, CM alkyl, cyano, hydroxy, CM alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-Ci-4 alkylamino; Y er O, S eller NR9, hvor R9 vælges blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, C1-4 alkylamino eller di-CM-alkylamino; omfattende
omdannelse af en forbindelse med formlen VIII
hvori Z er halogen, til en forbindelse med formlen VII. 12. Fremgangsmåden ifølge krav 11, kendetegnet ved, at forbindelsen med formlen VII opnås ved:
i) at reagere forbindelsen med formlen VIII
hvori Z er halogen, med Mg eller en organolithium-forbindelse, f.eks. n-BuLi, eller med et organometallisk kompleks bestående af Mg og/eller Mn og/eller Li og alkyl- eller arylgrupper for at opnå et første mellemprodukt;
ii) efterfølgende at reagere nævnte første mellemprodukt med CO2, CS2 eller en forbindelse med formlen IX
hvori A og X vælges uafhængigt blandt halid, CN, OR5 eller SR6, hvor R5 og R6 vælges uafhængigt blandt C1-0 alkyl, aiyl, heteroaryl eller benzyl og hver af disse C1-6 alkyl-, aryl-, heteroaryl- eller benzylgupper er usubstituerede eller substitueret med halogen, C1-4 alkyl, cyano, hydroxy, C1-4 alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino, NR7R8, hvor R7 og R8 vælges uafhængigt blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substituerede med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino; Y er O, S eller NR9, hvor R9 vælges blandt hydrogen, Cm alkyl, aryl, heteroaryl eller benzyl og hver af disse Cm alkyl-, aryl-, heteroaryl- eller benzylgrupper er usubstituerede eller substitueret med halogen, Cm alkyl, cyano, hydroxy, Cm alkoxy, trifluormethyl, nitro, amino, Cm alkylamino eller di-CM alkylamino; for at opnå forbindelsen med formlen VII. 13. Citalopram som basen eller ethvert hensigtsmæssigt salt deraf fremstillet ifølge fremgangsmåder ifølge et hvilket som helst af krav 1-7. 14. En farmaceutisk komposition omfattende citalopram som basen eller ethvert hensigtsmæssigt salt deraf ifølge krav 10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200101219A DK200101219A (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001231 | 2000-08-18 | ||
| DK200101219A DK200101219A (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200101219A true DK200101219A (da) | 2002-02-19 |
Family
ID=8159660
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200101216A DK200101216A (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
| DK200101219A DK200101219A (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
| DK01957786T DK1309582T3 (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
| DK01957785T DK1309581T3 (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200101216A DK200101216A (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01957786T DK1309582T3 (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
| DK01957785T DK1309581T3 (da) | 2000-08-18 | 2001-08-14 | Fremgangsmåde til fremstilling af citalopram |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6509483B2 (da) |
| EP (2) | EP1309582B1 (da) |
| JP (2) | JP2004506730A (da) |
| KR (2) | KR100887206B1 (da) |
| CN (3) | CN1239490C (da) |
| AR (3) | AR029598A1 (da) |
| AT (4) | ATE281447T1 (da) |
| AU (6) | AU7960801A (da) |
| BE (2) | BE1013443A6 (da) |
| BG (2) | BG65964B1 (da) |
| CA (2) | CA2354880C (da) |
| CH (2) | CH691969A5 (da) |
| CL (2) | CL2008002412A1 (da) |
| CZ (2) | CZ294746B6 (da) |
| DE (4) | DE60106933T2 (da) |
| DK (4) | DK200101216A (da) |
| EA (2) | EA005811B1 (da) |
| ES (4) | ES2230347T3 (da) |
| FI (2) | FI20011622L (da) |
| FR (2) | FR2813077B1 (da) |
| GB (2) | GB2365865B (da) |
| GR (1) | GR1004074B (da) |
| HK (2) | HK1044538B (da) |
| HR (2) | HRP20030065A2 (da) |
| HU (2) | HUP0103291A3 (da) |
| IE (2) | IES20010760A2 (da) |
| IL (2) | IL144817A0 (da) |
| IS (2) | IS2120B (da) |
| ME (2) | MEP2308A (da) |
| MX (2) | MXPA03001329A (da) |
| NL (2) | NL1018776C1 (da) |
| NO (2) | NO326570B1 (da) |
| NZ (2) | NZ523877A (da) |
| PL (2) | PL359825A1 (da) |
| PT (2) | PT1309581E (da) |
| RS (2) | RS50287B (da) |
| SI (2) | SI1309581T1 (da) |
| SK (2) | SK287236B6 (da) |
| UA (2) | UA72340C2 (da) |
| WO (2) | WO2002016341A1 (da) |
| ZA (1) | ZA200106683B (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR022329A1 (es) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | Metodo para la preparacion de 5-cianoftalida |
| NZ514671A (en) | 1999-04-14 | 2003-10-31 | H | Method for the preparation of citalopram |
| ITMI991581A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| EP1298124B1 (en) | 1999-10-25 | 2007-02-28 | H. Lundbeck A/S | Method For the Preparation of Citalopram |
| AR026063A1 (es) | 1999-11-01 | 2002-12-26 | Lundbeck & Co As H | Metodo para la preparacion de 5-carboxiftalida. |
| EA004742B1 (ru) | 1999-12-28 | 2004-08-26 | Х.Лундбекк А/С | Способ получения циталопрама |
| WO2001049672A1 (en) | 1999-12-30 | 2001-07-12 | H. Lundbeck A/S | Method for the preparation of citalopram |
| TR200201783T2 (tr) * | 2000-01-14 | 2002-12-23 | H. Lundbeck A/S | 5-Siyanofatalid hazırlamak için yöntem |
| NL1017417C1 (nl) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| NL1017500C1 (nl) | 2000-03-13 | 2001-04-26 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| KR20020080481A (ko) | 2000-03-13 | 2002-10-23 | 하. 룬트벡 아크티에 셀스카브 | 시탈로프람의 제조 방법 |
| CZ20023100A3 (cs) * | 2000-03-13 | 2003-02-12 | H. Lundbeck A/S | Způsob výroby citalopramu |
| SK14512002A3 (sk) | 2000-03-14 | 2003-03-04 | H. Lundbeck A/S | Spôsob výroby citalopramu, medziprodukt a citalopram výrobený týmto spôsobom |
| EP1274699A1 (en) * | 2000-03-16 | 2003-01-15 | H. Lundbeck A/S | Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| AR032455A1 (es) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
| IL144817A0 (en) | 2000-08-18 | 2002-06-30 | Lundbeck & Co As H | Method for the preparation of citalopram |
| JP3798982B2 (ja) | 2000-12-22 | 2006-07-19 | ハー・ルンドベック・アクチエゼルスカベット | 純粋なシタロプラムの製造方法 |
| WO2003057132A2 (en) * | 2002-01-07 | 2003-07-17 | Sun Pharmaceutical Industries Limited | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile |
| AR040970A1 (es) * | 2002-08-12 | 2005-04-27 | Lundbeck & Co As H | Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram |
| TR200504022T1 (tr) * | 2003-03-24 | 2006-08-21 | Hetero Drugs Limited | (S)-sitalopram oksalatın yeni sıvı kristal formları. |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| CN100569765C (zh) | 2003-12-19 | 2009-12-16 | 杭州民生药业集团有限公司 | 西酞普兰中间体晶体碱 |
| WO2009111031A2 (en) * | 2008-03-04 | 2009-09-11 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
| US20100087664A1 (en) * | 2008-10-07 | 2010-04-08 | Ravindra Vedantham | Preparation of citalopram and salts thereof |
| JP6222973B2 (ja) * | 2013-04-19 | 2017-11-01 | 日本テルペン化学株式会社 | ジベンジルトリチオカーボネート誘導体 |
| CN103936702A (zh) * | 2014-05-07 | 2014-07-23 | 成都诺维尔生物医药有限公司 | 艾司西酞普兰杂质j的合成方法 |
| EP3207018B1 (en) * | 2014-10-14 | 2018-07-25 | Syngenta Participations AG | Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone |
| CN118724848A (zh) * | 2023-03-29 | 2024-10-01 | 中国石油化工股份有限公司 | 一种制备2,5-呋喃二甲腈的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143703A (da) | 1965-03-18 | |||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| DE3926765A1 (de) | 1989-08-12 | 1991-02-14 | Hoechst Ag | Verfahren zur verminderung von primaerem und sekundaerem amin in einem tertiaeren amin |
| US5296507A (en) | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| DK213290D0 (da) | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | Treatment of cerebrovascular disorders |
| DE19626659A1 (de) | 1996-07-03 | 1998-01-08 | Basf Ag | Verfahren zur Herstellung von Phthaliden |
| DE19627697A1 (de) | 1996-07-10 | 1998-01-15 | Basf Ag | Verfahren zur Herstellung von Phthaliden |
| ZA9711376B (en) | 1996-12-20 | 1998-07-21 | Lundbeck & Co As H | Indole or dihydroindole derivatives |
| TR200000066T2 (tr) | 1997-07-08 | 2000-11-21 | H. Lundbeck A/S | Sitalopram hazırlanması için yöntem. |
| UA62985C2 (en) | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
| ES2149734T3 (es) * | 1997-11-11 | 2003-02-16 | Lundbeck & Co As H | Metodo para la preparacion de citalopram. |
| PL199423B1 (pl) | 1998-10-20 | 2008-09-30 | Lundbeck & Co As H | Sposób wytwarzania citalopramu |
| CN1149208C (zh) | 1998-12-23 | 2004-05-12 | H.隆德贝克有限公司 | 制备5-氰基2-苯并[c]呋喃酮的方法 |
| AR022329A1 (es) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | Metodo para la preparacion de 5-cianoftalida |
| NZ514671A (en) | 1999-04-14 | 2003-10-31 | H | Method for the preparation of citalopram |
| ITMI991581A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| ITMI991579A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| CH692298A5 (de) | 1999-10-25 | 2002-04-30 | Lundbeck & Co As H | Verfahren zur Herstellung von Zwischenstufen für die Citalopramsynthese sowie zur Herstellung von Escitalopram. |
| US6310222B1 (en) | 1999-11-01 | 2001-10-30 | Sumika Fine Chemicals Co., Ltd. | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate |
| NL1017415C1 (nl) | 2000-02-24 | 2001-05-18 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| IES20010143A2 (en) | 2000-02-24 | 2001-07-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
| GB0005477D0 (en) * | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
| IL144817A0 (en) | 2000-08-18 | 2002-06-30 | Lundbeck & Co As H | Method for the preparation of citalopram |
| JP3798982B2 (ja) | 2000-12-22 | 2006-07-19 | ハー・ルンドベック・アクチエゼルスカベット | 純粋なシタロプラムの製造方法 |
| CA2359810C (en) | 2000-12-28 | 2002-11-05 | H. Lundbeck A/S | Process for the preparation of pure citalopram |
-
2001
- 2001-08-09 IL IL14481701A patent/IL144817A0/xx not_active IP Right Cessation
- 2001-08-09 IL IL14481601A patent/IL144816A/xx not_active IP Right Cessation
- 2001-08-09 FI FI20011622A patent/FI20011622L/fi unknown
- 2001-08-09 CA CA002354880A patent/CA2354880C/en not_active Expired - Fee Related
- 2001-08-09 CA CA002354877A patent/CA2354877C/en not_active Expired - Fee Related
- 2001-08-09 FI FI20011621A patent/FI20011621A7/fi unknown
- 2001-08-10 IS IS6047A patent/IS2120B/is unknown
- 2001-08-10 HU HU0103291A patent/HUP0103291A3/hu unknown
- 2001-08-10 IS IS6048A patent/IS2121B/is unknown
- 2001-08-13 IE IE20010760A patent/IES20010760A2/en not_active IP Right Cessation
- 2001-08-13 HU HU0103295A patent/HUP0103295A3/hu unknown
- 2001-08-13 IE IE20010761A patent/IES20010761A2/en not_active IP Right Cessation
- 2001-08-14 HR HR20030065A patent/HRP20030065A2/xx not_active Application Discontinuation
- 2001-08-14 AU AU7960801A patent/AU7960801A/xx active Pending
- 2001-08-14 DK DK200101216A patent/DK200101216A/da not_active Application Discontinuation
- 2001-08-14 AT AT01957785T patent/ATE281447T1/de not_active IP Right Cessation
- 2001-08-14 NZ NZ523877A patent/NZ523877A/en unknown
- 2001-08-14 DK DK200101219A patent/DK200101219A/da not_active Application Discontinuation
- 2001-08-14 KR KR1020037002005A patent/KR100887206B1/ko not_active Expired - Fee Related
- 2001-08-14 NO NO20013943A patent/NO326570B1/no not_active IP Right Cessation
- 2001-08-14 EP EP01957786A patent/EP1309582B1/en not_active Expired - Lifetime
- 2001-08-14 ES ES01957785T patent/ES2230347T3/es not_active Expired - Lifetime
- 2001-08-14 EA EA200300277A patent/EA005811B1/ru not_active IP Right Cessation
- 2001-08-14 AU AU2001279608A patent/AU2001279608B2/en not_active Ceased
- 2001-08-14 HR HR20030064A patent/HRP20030064A2/xx not_active Application Discontinuation
- 2001-08-14 WO PCT/DK2001/000541 patent/WO2002016341A1/en not_active Ceased
- 2001-08-14 ZA ZA200106683A patent/ZA200106683B/xx unknown
- 2001-08-14 SI SI200130273T patent/SI1309581T1/xx unknown
- 2001-08-14 AU AU2001279609A patent/AU2001279609B2/en not_active Ceased
- 2001-08-14 JP JP2002521443A patent/JP2004506730A/ja not_active Withdrawn
- 2001-08-14 EA EA200300279A patent/EA005946B1/ru not_active IP Right Cessation
- 2001-08-14 ME MEP-23/08A patent/MEP2308A/xx unknown
- 2001-08-14 AU AU7960901A patent/AU7960901A/xx active Pending
- 2001-08-14 MX MXPA03001329A patent/MXPA03001329A/es active IP Right Grant
- 2001-08-14 DE DE60106933T patent/DE60106933T2/de not_active Expired - Lifetime
- 2001-08-14 JP JP2002521442A patent/JP2004506729A/ja not_active Withdrawn
- 2001-08-14 WO PCT/DK2001/000542 patent/WO2002016342A1/en not_active Ceased
- 2001-08-14 ME MEP-22/08A patent/MEP2208A/xx unknown
- 2001-08-14 KR KR1020037001900A patent/KR100887207B1/ko not_active Expired - Fee Related
- 2001-08-14 UA UA2003010797A patent/UA72340C2/uk unknown
- 2001-08-14 DK DK01957786T patent/DK1309582T3/da active
- 2001-08-14 MX MXPA03000913A patent/MXPA03000913A/es active IP Right Grant
- 2001-08-14 GB GB0119734A patent/GB2365865B/en not_active Expired - Fee Related
- 2001-08-14 PT PT01957785T patent/PT1309581E/pt unknown
- 2001-08-14 DE DE60106932T patent/DE60106932T2/de not_active Expired - Lifetime
- 2001-08-14 RS YUP-115/03A patent/RS50287B/sr unknown
- 2001-08-14 US US09/930,110 patent/US6509483B2/en not_active Expired - Fee Related
- 2001-08-14 GB GB0119733A patent/GB2362647B/en not_active Expired - Fee Related
- 2001-08-14 SK SK320-2003A patent/SK287236B6/sk not_active IP Right Cessation
- 2001-08-14 NZ NZ523853A patent/NZ523853A/en unknown
- 2001-08-14 DK DK01957785T patent/DK1309581T3/da active
- 2001-08-14 US US09/930,107 patent/US6426422B1/en not_active Expired - Fee Related
- 2001-08-14 SK SK322-2003A patent/SK287008B6/sk not_active IP Right Cessation
- 2001-08-14 RS YU6903A patent/RS50258B/sr unknown
- 2001-08-14 GR GR20010100398A patent/GR1004074B/el unknown
- 2001-08-14 PL PL35982501A patent/PL359825A1/xx not_active Application Discontinuation
- 2001-08-14 SI SI200130272T patent/SI1309582T1/xx unknown
- 2001-08-14 AT AT01957786T patent/ATE281448T1/de not_active IP Right Cessation
- 2001-08-14 EP EP01957785A patent/EP1309581B1/en not_active Expired - Lifetime
- 2001-08-14 ES ES01957786T patent/ES2228920T3/es not_active Expired - Lifetime
- 2001-08-14 PT PT01957786T patent/PT1309582E/pt unknown
- 2001-08-14 NO NO20013942A patent/NO326772B1/no not_active IP Right Cessation
- 2001-08-14 UA UA2003010798A patent/UA71676C2/uk unknown
- 2001-08-14 PL PL35996901A patent/PL359969A1/xx not_active Application Discontinuation
- 2001-08-15 CZ CZ20012958A patent/CZ294746B6/cs not_active IP Right Cessation
- 2001-08-15 CZ CZ20012959A patent/CZ295863B6/cs not_active IP Right Cessation
- 2001-08-15 AU AU2001100271A patent/AU2001100271B4/en not_active Expired
- 2001-08-16 DE DE10140029A patent/DE10140029A1/de not_active Withdrawn
- 2001-08-16 FR FR0110855A patent/FR2813077B1/fr not_active Expired - Fee Related
- 2001-08-16 FR FR0110857A patent/FR2813078B1/fr not_active Expired - Fee Related
- 2001-08-16 CH CH01522/01A patent/CH691969A5/de not_active IP Right Cessation
- 2001-08-16 CH CH01521/01A patent/CH691968A5/de not_active IP Right Cessation
- 2001-08-16 NL NL1018776A patent/NL1018776C1/nl not_active IP Right Cessation
- 2001-08-16 AU AU2001100278A patent/AU2001100278B4/en not_active Expired
- 2001-08-16 BE BE2001/0548A patent/BE1013443A6/fr not_active IP Right Cessation
- 2001-08-16 AR ARP010103924A patent/AR029598A1/es not_active Application Discontinuation
- 2001-08-16 NL NL1018775A patent/NL1018775C1/nl not_active IP Right Cessation
- 2001-08-16 DE DE10140028A patent/DE10140028A1/de not_active Withdrawn
- 2001-08-16 AR ARP010103923A patent/AR029597A1/es not_active Application Discontinuation
- 2001-08-17 CN CNB2004100018711A patent/CN1239490C/zh not_active Expired - Fee Related
- 2001-08-17 CN CNB011339489A patent/CN1222517C/zh not_active Expired - Fee Related
- 2001-08-17 AT AT0065101U patent/AT5026U1/de not_active IP Right Cessation
- 2001-08-17 ES ES200101919A patent/ES2170734B2/es not_active Expired - Fee Related
- 2001-08-17 CN CNB011339470A patent/CN1159307C/zh not_active Expired - Fee Related
- 2001-08-17 ES ES200101920A patent/ES2170735B2/es not_active Expired - Fee Related
- 2001-08-17 AT AT0065001U patent/AT4946U1/de not_active IP Right Cessation
- 2001-08-20 BE BE2001/0550A patent/BE1013444A6/fr not_active IP Right Cessation
-
2002
- 2002-08-22 HK HK02106176.1A patent/HK1044538B/zh not_active IP Right Cessation
- 2002-09-04 HK HK02106522.2A patent/HK1047086B/zh not_active IP Right Cessation
-
2003
- 2003-02-24 BG BG107583A patent/BG65964B1/bg unknown
- 2003-02-24 BG BG107584A patent/BG65965B1/bg unknown
-
2008
- 2008-04-25 AR ARP080101772A patent/AR066694A2/es unknown
- 2008-08-14 CL CL2008002412A patent/CL2008002412A1/es unknown
- 2008-09-09 CL CL2008002673A patent/CL2008002673A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200101216A (da) | Fremgangsmåde til fremstilling af citalopram | |
| Yang et al. | Visible-light initiated direct oxysulfonylation of alkenes with sulfinic acids leading to β-ketosulfones | |
| Miao et al. | Recent Advances in First‐Row‐Transition‐Metal‐Catalyzed Dehydrogenative Coupling of C (sp3)–H Bonds | |
| Liao et al. | Iodine-catalyzed efficient 2-arylsulfanylphenol formation from thiols and cyclohexanones | |
| Henderson et al. | Magnesium bisamides as reagents in synthesis | |
| Liu et al. | Recent progress in organophotoredox reaction | |
| RU2013107023A (ru) | Способ получения производных аминобензоилбензофурана | |
| AU2003257302A1 (en) | Phosphonium and imidazolium salts and methods of their preparation | |
| MXPA05013452A (es) | Proceso para preparar derivados de 4'-azidonucleosido. | |
| TR200202048T2 (tr) | Sitalopramin preparasyon metodu. | |
| Ghatak et al. | Thorium complexes possessing expanded ring N-heterocyclic iminato ligands: synthesis and applications | |
| PT1442006E (pt) | Preparacao de anfetaminas a partir de fenilpropanolaminas | |
| Cai et al. | Visible-light-driven reductive dearomatization of N-arylformyl indoles in EDA complexes with a thiophenol via a HAT pathway | |
| Yang et al. | Catalytic enantioselective desymmetrization of meso-aziridines | |
| EA200701470A1 (ru) | Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений | |
| Mansaray et al. | Efficient enantioselective synthesis of trisubstituted γ-lactam via the Michael addition reaction of 2, 3-dioxopyrrolidine with indole in aqueous media | |
| RU2007133721A (ru) | Способ получения 2, 3-дизамещенных индолов | |
| CN111303114B (zh) | 一种合成3-磺酰化硫代黄酮类化合物的合成方法 | |
| CN102260200A (zh) | 一种苯砜类化合物的合成方法 | |
| Ibrahim et al. | Recent advances and prospects in the amination of benzoxazoles | |
| CN116730938A (zh) | 一种合成5-羟甲基恶唑烷酮的方法 | |
| JP2003529543A5 (da) | ||
| CA2531167A1 (en) | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | |
| CN117164627B (zh) | 含三氟甲基季碳中心的酮膦氧化合物及其制备方法与应用 | |
| DE502005003737D1 (de) | Leitsalze fur galvanische zellen, deren herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ATS | Application withdrawn |















